Daily EPS Performer Reports
Stocks detected early by our EPS revision screener — and how they performed.
Bloom Energy Surges 37% After EPS Upgrade; Travere Jumps 31%
Bloom Energy led today's movers with a 37.3% surge to $219.88 after its forward EPS projection was raised 1.5 percentage points to 108.4%. Travere Therapeutics followed with a 31.4% gain to $41.63, driven by a 29.1 percentage point EPS revision lift to 548.8%. Both healthcare and industrial names showed strength, with smaller-cap biotech EVO and materials stock RMIX each climbing over 21%.
Read analysis →FFAI Surges 50% After Analyst EPS Upgrade Leads Industrial, Healthcare Reversals
Faraday Future (FFAI) led today's movers with a 50% gain after analysts revised EPS growth estimates 12.9 percentage points higher to 63.2%, signaling improved capital efficiency in EV operations. Keel Infrastructure (KEEL) gained 34.3% on 43.7% EPS growth projections, while Travere Therapeutics (TVTX) surged 29.8% following a 29.1pp EPS revision to 548.8%—the largest proportional estimate upgrade of the session. Bloom Energy (BE) added 27.4% with the Oracle AI data center power deal providing a concrete news catalyst that reinforced its 108.4% EPS forecast.
Read analysis →SPIR Soars 44.5% as Analysts Double Earnings Growth Forecast to 95.6%
EPS estimate revisions drove explosive moves across small-cap stocks this week, with SPIR leading at +44.5% after its next-year earnings growth projection nearly doubled from 58.9% to 95.6%. Faraday Future jumped 40.9% on a 12.9pp revision, while Avis Budget gained 32% despite a modest 4.1pp EPS upgrade, signaling strong conviction in travel-sector profitability. The Industrials sector dominated with three of five top performers.
Read analysis →FFAI Rockets 50% After Analyst Hike; SLNO, SPIR Lead Healthcare & Industrials Higher
FFAI surged 50% to $0.33 after analysts revised next-year EPS estimates up 12.9 percentage points to 63.2%, marking the biggest single-stock move in today's screening data. SLNO followed with a 33% rally to $52.51 as EPS estimates climbed 9.5pp to 68.7%, while SPIR added 28.7% to $20.48 after a near-doubling of its EPS growth forecast from 58.9% to 95.6%. Healthcare names INBX and biotech SLNO broadly outperformed, suggesting positive sentiment in speculative growth names.
Read analysis →